Chimeric Therapeutics Ltd Asset Resilience Ratio
Chimeric Therapeutics Ltd asset resilience ratio. Chimeric Therapeutics Ltd (CHM) has an Asset Resilience Ratio of 42.22% as of December 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See operational self-sufficiency of Chimeric Therapeutics Ltd to measure how many days the company can operate on defensive assets alone.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio of Chimeric Therapeutics Ltd (2021–2022)
Asset resilience ratio of Chimeric Therapeutics Ltd from 2021 to 2022. This chart shows how Chimeric Therapeutics Ltd's Asset Resilience Ratio has changed over time. Read Chimeric Therapeutics Ltd debt and liabilities for a breakdown of total debt and financial obligations.
Liquid Assets Composition Over Time
This chart breaks down Chimeric Therapeutics Ltd's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For the complete balance sheet picture, see Chimeric Therapeutics Ltd total assets.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | AU$2.50 Million | 42.22% |
| Short-term Investments | AU$0.00 | 0% |
| Total Liquid Assets | AU$2.50 Million | 42.22% |
Asset Resilience Insights
- Very High Liquidity: Chimeric Therapeutics Ltd maintains exceptional liquid asset reserves at 42.22% of total assets.
- This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
- The company primarily holds liquidity in cash and equivalents rather than short-term investments.
Chimeric Therapeutics Ltd Industry Peers by Asset Resilience Ratio
Compare Chimeric Therapeutics Ltd's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Samsung Biologics Co Ltd
KO:207940 |
Biotechnology | 15.21% |
|
Verona Pharma plc
F:I9SA |
Biotechnology | 0.00% |
|
Asymchem Laboratories Tian Jin Co Ltd
SHE:002821 |
Biotechnology | 5.07% |
|
Immunovant Inc
NASDAQ:IMVT |
Biotechnology | 98.50% |
|
Shanghai Allist Pharmaceuticals Co. Ltd. A
SHG:688578 |
Biotechnology | 21.11% |
|
Tubize-Fin
BR:TUB |
Biotechnology | 2.50% |
|
Shanghai RAAS Blood Products Co Ltd Class A
SHE:002252 |
Biotechnology | 2.03% |
|
Amicus Therapeutics Inc
NASDAQ:FOLD |
Biotechnology | 8.37% |
Chimeric Therapeutics Ltd Asset Resilience Ratio by Year (2021–2022)
Chimeric Therapeutics Ltd asset resilience ratio by year from 2021 to 2022. The table below shows the annual Asset Resilience Ratio data for Chimeric Therapeutics Ltd.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2022-06-30 | 52.70% | AU$18.38 Million ≈ $13.01 Million |
AU$34.88 Million ≈ $24.68 Million |
-8.69pp |
| 2021-06-30 | 61.39% | AU$22.41 Million ≈ $15.86 Million |
AU$36.50 Million ≈ $25.83 Million |
-- |
About Chimeric Therapeutics Ltd
Chimeric Therapeutics Limited, a clinical stage cell therapy company, develops and commercializes a range of cell therapies for oncology in Australia. The company develops CHM CDH17-directed CAR T cell therapy for the treatment of advanced colorectal cancer, gastric cancer, and intestinal neuroendocrine tumors; and CHM CLTX, a chlorotoxin-directed CAR T cell therapy to treat patients with recurre… Read more